Researchers from Curacle Co. Ltd. and Yonsei University have published preclinical data for the endothelial dysfunction blocker CU06-1004 from studies assessing it in models of retinal vascular disease.
Roquefort Therapeutics plc's ROQ-A1 and ROQ-A2 Midkine (MDK) antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in preclinical development programs conducted by cancer research groups.
Unexpected behavior of neutrophils unveiled by researchers at Stanford University could lead to a new type of immunotherapy to treat cancer. Although various studies have suggested that these cells are harmful due to their immunosuppressive characteristics, the scientists saw in them an opportunity to redirect them and eliminate tumors.
UCB SA has identified imidazotriazine derivatives acting as IL-17 modulators reported to be useful for the treatment of autoimmune and inflammatory disorders.
Medshine Discovery Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moieties covalently linked to bromodomain-containing protein 4 (BRD4; HUNK1) targeting moieties through a linker reported to be useful for the treatment of cancer.
Korea University Research and Business Foundation (KURBF) has disclosed peptides acting as apoptosis inducers reported to be useful for the treatment of cancer.
Inmune Bio Inc., together with a collaborator at University of California, Irvine School of Medicine, has shown targeting soluble TNF (sTNF) using a dominant-negative TNF (DN-TNF) biologic significantly decreased muscle damage in a murine mdx model of Duchenne muscular dystrophy (DMD) and showed a statistically significant increase in muscle regeneration.
RSS
